Alps Advisors Inc Crinetics Pharmaceuticals, Inc. Transaction History

Alps Advisors Inc

$17.2 Billion
Q2 2025

A detailed history of Alps Advisors Inc transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 50,524 shares of CRNX stock, worth $2.24 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

50,524

Previous 67,303 24.93%

Holding current value

$2.24 Million

Previous $2.26 Million 35.62%

% of portfolio

0.01%

Previous 0.01%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 11, 2025	SELL	$25.56 - $33.76 $428,871 - $566,459	-16,779 Reduced 24.93%	50,524 $1.45 Million
Q1 2025 Apr 30, 2025	SELL	$32.3 - $53.15 $248,128 - $408,298	-7,682 Reduced 10.24%	67,303 $2.26 Million
Q4 2024 Feb 13, 2025	BUY	$50.66 - $60.69 $721,499 - $864,346	14,242 Added 23.45%	74,985 $3.83 Million
Q3 2024 Nov 12, 2024	SELL	$43.83 - $54.98 $34,275 - $42,994	-782 Reduced 1.27%	60,743 $3.1 Million
Q2 2024 Aug 13, 2024	BUY	$42.12 - $51.91 $276,138 - $340,321	6,556 Added 11.93%	61,525 $2.76 Million
Q1 2024 May 14, 2024	BUY	$34.76 - $46.81 $310,893 - $418,668	8,944 Added 19.43%	54,969 $2.57 Million
Q4 2023 Feb 14, 2024	BUY	$25.62 - $37.07 $145,957 - $211,187	5,697 Added 14.13%	46,025 $1.64 Million
Q3 2023 Nov 14, 2023	BUY	$15.97 - $30.59 $9,869 - $18,904	618 Added 1.56%	40,328 $1.2 Million
Q2 2023 Aug 14, 2023	BUY	$15.73 - $23.6 $65,908 - $98,884	4,190 Added 11.8%	39,710 $715,000
Q1 2023 May 10, 2023	SELL	$15.31 - $21.1 $14,651 - $20,192	-957 Reduced 2.62%	35,520 $570,000
Q4 2022 Feb 14, 2023	BUY	$15.49 - $19.05 $110,768 - $136,226	7,151 Added 24.38%	36,477 $667,000
Q3 2022 Nov 14, 2022	SELL	$18.11 - $22.37 $43,717 - $54,001	-2,414 Reduced 7.61%	29,326 $576,000
Q2 2022 Aug 11, 2022	SELL	$16.49 - $27.64 $281,566 - $471,953	-17,075 Reduced 34.98%	31,740 $592,000
Q1 2022 May 16, 2022	SELL	$17.15 - $28.31 $105,455 - $174,078	-6,149 Reduced 11.19%	48,815 $1.07 Million
Q4 2021 Feb 09, 2022	BUY	$19.35 - $28.41 $145,666 - $213,870	7,528 Added 15.87%	54,964 $1.56 Million
Q3 2021 Nov 15, 2021	SELL	$16.88 - $25.23 $35,110 - $52,478	-2,080 Reduced 4.2%	47,436 $999,000
Q2 2021 Aug 11, 2021	SELL	$15.9 - $21.15 $159,747 - $212,494	-10,047 Reduced 16.87%	49,516 $933,000
Q1 2021 May 07, 2021	BUY	$13.3 - $17.55 $1,675 - $2,211	126 Added 0.21%	59,563 $910,000
Q4 2020 Feb 03, 2021	BUY	$12.08 - $17.46 $211,436 - $305,602	17,503 Added 41.74%	59,437 $839,000
Q3 2020 Nov 04, 2020	SELL	$13.62 - $17.66 $39,157 - $50,772	-2,875 Reduced 6.42%	41,934 $657,000
Q2 2020 Aug 05, 2020	BUY	$13.04 - $23.23 $10,027 - $17,863	769 Added 1.75%	44,809 $785,000
Q1 2020 May 06, 2020	SELL	$11.52 - $26.46 $59,120 - $135,792	-5,132 Reduced 10.44%	44,040 $647,000
Q4 2019 Feb 07, 2020	BUY	$15.24 - $25.09 $14,554 - $23,960	955 Added 1.98%	49,172 $1.23 Million
Q3 2019 Nov 04, 2019	SELL	$14.91 - $25.01 $34,412 - $57,723	-2,308 Reduced 4.57%	48,217 $725,000
Q2 2019 Aug 07, 2019	BUY	$21.48 - $27.71 $1.09 Million - $1.4 Million	50,525 New	50,525 $1.26 Million

Others Institutions Holding CRNX

# of Institutions

238

Shares Held

90.2M

Call Options Held

59.7K

Put Options Held

14.8K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.38B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.

Account

Alps Advisors Inc Crinetics Pharmaceuticals, Inc. Transaction History